5-(3-(1H-imidazol-1-yl)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one | 1542066-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3-(1H-imidazol-1-yl)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one
• 英文别名: 5-(3-(1H-imidazole)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazole-6(1H)-one；4-(4-bromophenyl)-1-[(4-fluorophenyl)methyl]-4,5-dihydro-5-[3-(1H-imidazol-1-yl)propyl]-3-phenylpyrrolo[3,4-c]pyrazol-6(1H)-one；CAY10682；4-(4-bromophenyl)-1-[(4-fluorophenyl)methyl]-4,5-dihydro-5-[3-(1H-imidazol-1-yl)propyl]-3-phenyl-pyrrolo[3,4-c]pyrazol-6(1H)-one；4-(4-bromophenyl)-1-[(4-fluorophenyl)methyl]-5-(3-imidazol-1-ylpropyl)-3-phenyl-4H-pyrrolo[3,4-c]pyrazol-6-one
• CAS: 1542066-74-9；1612187-52-6；1612187-54-8
• 化学式: C₃₀H₂₅BrFN₅O
• 分子量: 570.464
• InChiKey: WBTRUQGSTZSFSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(3-(1H-imidazol-1-yl)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 在 Chiralcel AD-H 作用下， 以 甲醇 为溶剂， 生成 (-)-5-(3-(1H-imidazole)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazole-6(1H)-one 、 (-)-5-(3-(1H-imidazole)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazole-6(1H)-one
  参考文献：
  名称：

  吡咯酮并吡唑类化合物及其作为药物的用途

  摘要：

  本发明属于医药技术领域。本发明提供了一种吡咯酮类化合物，包括其光学异构体、外消旋体、顺反异构体以及任意组合或其药用盐，结构如式(Ⅰ)所示。本发明的化合物可作为p53‑MDM2/X蛋白相互作用小分子抑制剂。本发明的化合物可用于制备抗肿瘤药物或抗炎药物。

  公开号：

  CN103819476B
• 作为产物：
  描述：

  4-benzoyl-5-(4-bromophenyl)-3-hydroxy-1-[3-(1H-imidazol-1-yl)propyl]-2,5-dihydro-1H-pyrrol-2-one 在 potassium carbonate 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 14.25h， 生成 5-(3-(1H-imidazol-1-yl)propyl)-4-(4-bromophenyl)-1-(4-fluorobenzyl)-3-phenyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one
  参考文献：
  名称：

  Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway

  摘要：

  Simultaneous inactivation of p53 and hyperactivation of nuclear factor-kappa B (NF-kappa B) is a common occurrence in human cancer. Currently, antitumor agents are being designed to selectively activate p53 or inhibit NF-kappa B. However, there is no concerted effort yet to deliberately design inhibitors that can simultaneously do both. This paper provided a proof-of-concept study that p53-MDM2 interaction and NF-kappa B pathway can be simultaneously targeted by a small-molecule inhibitor. A series of pyrrolo[3,4-c]pyrazole derivatives were rationally designed and synthesized as the first-in-class inhibitors of p53-MDM2 interaction and NF-kappa B pathway. Most of the compounds were identified to possess nanomolar p53-MDM2 inhibitory activity. Compounds 5q and 5s suppressed NF-kappa B activation through inhibition of I kappa B alpha phosphorylation and elevation of the cytoplasmic levels of p65 and phosphorylated IKK alpha/beta. Biochemical assay for the kinases also supported the fact that pyrrolo[3,4-c]pyrazole compounds directly targeted the NF-kappa B pathway. In addition, four compounds (5j, 5q, 5s, and 5u) effectively inhibited tumor growth in the A549 xenograft model. Further pharmacokinetic study revealed that compound 5q exhibited excellent oral bioavailability (72.9%).

  DOI：

  10.1021/jm401800k

文献信息

• [EN] PYRROLIDONOPYRAZOLE COMPOUNDS AND USE THEREOF AS DRUGS<br/>[FR] COMPOSÉS PYRROLIDONOPYRAZOLES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：UNIV PLA 2ND MILITARY MEDICAL

  公开号：WO2014134968A1

  公开（公告）日：2014-09-12

  本发明属于医药技术领域。本发明提供了一种吡咯酮类化合物，包括其光学异构体、外消旋体、顺反异构体以及任意组合或其药用盐，结构如式（I）所示。本发明的化合物可作为p53-MDM2/X蛋白相互作用小分子抑制剂。本发明的化合物可用于制备抗肿瘤药物或抗炎药物。
• COMPOSITIONS AND METHODS FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS
  申请人：Unity Biotechnology, Inc.

  公开号：US20180193458A1

  公开（公告）日：2018-07-12

  Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
• PROTOCOL FOR INCREASING LIFE EXPECTANCY IN A TEST SUBJECT
  申请人：Mayo Foundation for Medical Education and Research

  公开号：US20190022225A1

  公开（公告）日：2019-01-24

  Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
• Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway
  作者：Chunlin Zhuang、Zhenyuan Miao、Yuelin Wu、Zizhao Guo、Jin Li、Jianzhong Yao、Chengguo Xing、Chunquan Sheng、Wannian Zhang

  DOI：10.1021/jm401800k

  日期：2014.2.13

  Simultaneous inactivation of p53 and hyperactivation of nuclear factor-kappa B (NF-kappa B) is a common occurrence in human cancer. Currently, antitumor agents are being designed to selectively activate p53 or inhibit NF-kappa B. However, there is no concerted effort yet to deliberately design inhibitors that can simultaneously do both. This paper provided a proof-of-concept study that p53-MDM2 interaction and NF-kappa B pathway can be simultaneously targeted by a small-molecule inhibitor. A series of pyrrolo[3,4-c]pyrazole derivatives were rationally designed and synthesized as the first-in-class inhibitors of p53-MDM2 interaction and NF-kappa B pathway. Most of the compounds were identified to possess nanomolar p53-MDM2 inhibitory activity. Compounds 5q and 5s suppressed NF-kappa B activation through inhibition of I kappa B alpha phosphorylation and elevation of the cytoplasmic levels of p65 and phosphorylated IKK alpha/beta. Biochemical assay for the kinases also supported the fact that pyrrolo[3,4-c]pyrazole compounds directly targeted the NF-kappa B pathway. In addition, four compounds (5j, 5q, 5s, and 5u) effectively inhibited tumor growth in the A549 xenograft model. Further pharmacokinetic study revealed that compound 5q exhibited excellent oral bioavailability (72.9%).
• 吡咯酮并吡唑类化合物及其作为药物的用途
  申请人：中国人民解放军第二军医大学

  公开号：CN103819476B

  公开（公告）日：2016-08-17

  本发明属于医药技术领域。本发明提供了一种吡咯酮类化合物，包括其光学异构体、外消旋体、顺反异构体以及任意组合或其药用盐，结构如式(Ⅰ)所示。本发明的化合物可作为p53‑MDM2/X蛋白相互作用小分子抑制剂。本发明的化合物可用于制备抗肿瘤药物或抗炎药物。